Literature DB >> 8071338

Kunitz domain inhibitors of tissue factor-factor VIIa. II. Potent and specific inhibitors by competitive phage selection.

M S Dennis1, R A Lazarus.   

Abstract

Active-site inhibitors of the human tissue factor-Factor VIIa complex (TF.FVIIa) that are both potent and specific have been selected from Alzheimer's amyloid beta-protein precursor inhibitor (APPI) Kunitz domain libraries using a strategy termed competitive phage selection. Phage display Libraries I-III, previously sorted by direct selection, were sorted by competitive selection against immobilized TF.FVIIa in which increasing amounts of Factor XIa (FXIa) were added to the selection buffer to remove phage with high affinity for FXIa. The most striking difference in the selected Kunitz domain sequences was at the P4' position where Lys was highly preferred instead of Leu which was found here by direct selection (Dennis, M. S., and Lazarus, R. A. (1994) J. Biol. Chem. 269, 22129-22136). In addition, both Lys and Arg were selected in the P1 position as opposed to Arg alone. A new library (Library IV) was constructed which contained all previously observed amino acids at 9 positions in the primary and secondary binding loops of APPI. Comparable results were obtained by sorting Library IV against immobilized TF.FVIIa in the presence of either FXIa alone or FXIa, plasma kallikrein, and plasmin. The Kunitz domains obtained by either competitive selection strategy potently inhibited TF.FVIIa, with Ki* values ranging from about 2 to 20 nM; the Ki* values were generally > 1 microM for FXIa and plasma kallikrein and ranged from 4 to 200 nM for plasmin. Variants selective for TF.FVIIa were assayed for free FVIIa and FXa inhibitory activity and characterized in coagulation assays. A rationale for the selection of Lys at both the P4' and P1 positions based upon comparison of sequences and structures of relevant serine proteases and inhibitors is presented.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8071338

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  13 in total

Review 1.  The pharmacological landscape and therapeutic potential of serine hydrolases.

Authors:  Daniel A Bachovchin; Benjamin F Cravatt
Journal:  Nat Rev Drug Discov       Date:  2012-01-03       Impact factor: 84.694

2.  Mechanisms and specificity of factor XIa and trypsin inhibition by protease nexin 2 and basic pancreatic trypsin inhibitor.

Authors:  Duraiswamy Navaneetham; Dipali Sinha; Peter N Walsh
Journal:  J Biochem       Date:  2010-07-20       Impact factor: 3.387

Review 3.  A new generation of protein display scaffolds for molecular recognition.

Authors:  Ralf J Hosse; Achim Rothe; Barbara E Power
Journal:  Protein Sci       Date:  2006-01       Impact factor: 6.725

4.  Characterization of engineered hepatitis C virus NS3 protease inhibitors affinity selected from human pancreatic secretory trypsin inhibitor and minibody repertoires.

Authors:  N Dimasi; F Martin; C Volpari; M Brunetti; G Biasiol; S Altamura; R Cortese; R De Francesco; C Steinkühler; M Sollazzo
Journal:  J Virol       Date:  1997-10       Impact factor: 5.103

5.  Structure of an Fab-protease complex reveals a highly specific non-canonical mechanism of inhibition.

Authors:  Christopher J Farady; Pascal F Egea; Eric L Schneider; Molly R Darragh; Charles S Craik
Journal:  J Mol Biol       Date:  2008-05-11       Impact factor: 5.469

Review 6.  Mechanisms of macromolecular protease inhibitors.

Authors:  Christopher J Farady; Charles S Craik
Journal:  Chembiochem       Date:  2010-11-22       Impact factor: 3.164

7.  Obtaining a family of high-affinity, high-specificity protein inhibitors of plasmin and plasma kallikrein.

Authors:  A C Ley; W Markland; R C Ladner
Journal:  Mol Divers       Date:  1996-10       Impact factor: 2.943

8.  The mechanism of inhibition of antibody-based inhibitors of membrane-type serine protease 1 (MT-SP1).

Authors:  Christopher J Farady; Jeonghoon Sun; Molly R Darragh; Susan M Miller; Charles S Craik
Journal:  J Mol Biol       Date:  2007-04-04       Impact factor: 5.469

9.  Combinatorial protein engineering of proteolytically resistant mesotrypsin inhibitors as candidates for cancer therapy.

Authors:  Itay Cohen; Olumide Kayode; Alexandra Hockla; Banumathi Sankaran; Derek C Radisky; Evette S Radisky; Niv Papo
Journal:  Biochem J       Date:  2016-03-08       Impact factor: 3.857

Review 10.  Tissue factor: a key molecule in hemostatic and nonhemostatic systems.

Authors:  James H Morrissey
Journal:  Int J Hematol       Date:  2004-02       Impact factor: 2.490

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.